GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citize... ( PHILADELPHIA Oct. 30 /- GlaxoSmit...)

GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition

Date:10/30/2008

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on AVANDIA(R) (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

The safety of patients using our medicine is very important to us. On a continual basis, an external Hepatic Safety Board reviews any adverse event report received by GSK of liver failure, liver-related deaths and liver transplants for possible relationship to AVANDIA. As recently as July 2008, this panel of experts continued to endorse a favorable hepatic safety profile for AVANDIA.

Patients being treated with AVANDIA or other medicines to control blood sugar levels should remain on therapy, unless their doctor advises a different course of action.

AVANDIA has been shown to be a safe and highly effective treatment for type 2 diabetes for the appropriate patient. GSK strongly supports the safety and efficacy of AVANDIA based on extensive clinical trial experience and widespread post-marketing use. The record of safety and effectiveness of AVANDIA is backed by one of the largest clinical trial programs (including 52,000 patients) ever undertaken for any medicine.

Data from long-term clinical trials, which offer the most rigorous scientific measurement of safety and efficacy, provide substantial evidence to assess the benefit-risk of AVANDIA in treating patients with diabetes. Importantly, the Public Citizen petition did not include data from the current Prescribing Information for AVANDIA regarding ADOPT (A Diabetes Outcomes Progression Trial). ADOPT, the largest head-to-head diabetes trial, showed that AVANDIA sustained glycemic control longer than metformin or sulfonylurea, for up to five years. Additionally, outcomes from five long-term clinical studies did not demonstrate an increased risk of t
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
3. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
4. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
5. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
6. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
11. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa

Post Your Comments:

GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citize...( PHILADELPHIA Oct. 30 /- GlaxoSmit...),Health